UNSPSC 85252711: Diagnosis of secondary malignant neoplasm of bone and bone marrow

This classification denotes the group of activities that yields a diagnosis of Secondary malignant neoplasm of bone and bone marrow. Secondary malignant neoplasm of bone and bone marrow is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as a four digit category under code C79. 5

UNSPSC 85252711 Diagnosis of secondary malignant neoplasm of bone and bone marrow is a Commodity code showing limited direct alignment with recent state and local contract activity. The code nominally describes diagnostic services for a specific oncologic condition, but the recent opportunities posted under it reflect broader health professional staffing and diagnostic imaging infrastructure procurement rather than the narrow bone and bone marrow pathology diagnosis the code name suggests. State and local health systems, counties, and school districts are the primary issuing bodies soliciting related services; however, the three most recent opportunities—a diagnostic imaging PACS system implementation, a special education contracted services pool, and a health professional temporary staffing qualification vehicle—span different clinical domains and purchasing models that do not cleanly map to the code's stated scope.

Geographic activity appears concentrated in California (San Mateo County and Santa Clara County health systems) with activity also in Texas (Birdville Independent School District). The San Mateo Medical Center issued an RFP (due October 21, 2026) for an enterprise diagnostic imaging PACS system supporting radiology, cardiology, and dental imaging with EPIC integration, requiring vendor demonstration of prior PACS implementations in public health systems and three to five client references. The County of Santa Clara Health System posted a non-exclusive multiple-award qualification vehicle (due October 7, 2026) to establish a temporary health professional staffing pool across ancillary categories including diagnostic imaging/radiology, audiology, and therapy services, with no guaranteed work volume and case-by-case scope negotiation. The code shows little relevant recent activity specific to secondary bone and bone marrow malignancy diagnosis; procurement activity under this classification appears to reflect broader diagnostic, imaging, and clinical staffing sourcing rather than narrow pathology-specific diagnostic services.